Orthofix Medical Inc. insider trading
Every open-market purchase and sale by Orthofix Medical Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Orthofix Medical Inc.’s insiders pay?
From March 11, 2010 to September 22, 2026, 45 insiders reported 33 open-market purchases and 63 sales not made under a pre-set plan in Orthofix Medical Inc. Twelve months after each purchase was reported, the shares were −11.4% against the S&P 500 on average (median −5.3%), over 29 purchases with a full year of prices; 31% beat the index. After sales, the shares moved −32.4% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on September 2, 2010 into $5,086 by November 2, 2026, −4.1% a year. It held shares 65% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $37,898 (+8.6% a year), and held throughout $92,007 (+14.8%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Finegan Michael | Chief Strategy Officer | 0 | — | — | 9 | −44.2% (9) | June 9, 2020 |
| Ferrari Luigi | President, Orthopedics | 0 | — | — | 8 | −34.6% (8) | August 21, 2012 |
| Mason Brad | CEO | 1 | −1.7% (1) | 0% | 5 | −12.6% (5) | August 29, 2019 |
| Calafiore Massimo | President & CEO | 2 | −38.7% (2) | 0% | 3 | −39.7% (1) | March 6, 2026 |
| Matricaria Ronald A | Director | 4 | +0.8% (4) | 50% | 0 | — | March 18, 2020 |
| Andrews Julie | CFO | 0 | — | — | 3 | −42.5% (1) | March 6, 2026 |
| Cedron Jorge Andres | CLO | 0 | — | — | 3 | −46.0% (1) | April 20, 2026 |
| Fisher Patrick | President, Global Limb Recon | 0 | — | — | 3 | −54.2% (1) | August 20, 2026 |
| Hinrichs James F. | Director | 3 | +18.5% (3) | 67% | 0 | — | September 14, 2023 |
| Lee Brad | President, Sports Medicine GBU | 0 | — | — | 3 | −45.5% (3) | May 7, 2012 |
| Mcpherron Aviva | Pres, Global Ops & Qual | 0 | — | — | 3 | −37.5% (1) | June 22, 2026 |
| Vitale Lucas | CP&BOO | 0 | — | — | 3 | −46.7% (1) | March 19, 2026 |
| Bazaar Alan Lee | Director | 2 | −32.5% (2) | 0% | 0 | — | June 5, 2025 |
| Brown Eric | President, Spinal Stimulation | 0 | — | — | 2 | −24.9% (2) | March 12, 2010 |
| Elting Kimberley A. | Chief Legal & Develop. Officer | 1 | −31.7% (1) | 0% | 1 | −39.6% (1) | November 18, 2021 |
| Faulstick Luke T | Director | 0 | — | — | 2 | −15.0% (2) | November 6, 2018 |
| Juniper Investment Company, LLC | 10% owner | 0 | — | — | 2 | — | September 22, 2026 |
| Mainelli Michael | Director | 2 | +9.2% (2) | 100% | 0 | — | May 15, 2013 |
| Niemann Bradley V. | President of Global Spine | 0 | — | — | 2 | −23.1% (2) | July 5, 2018 |
| Reinhardt Max | President, Global Spine | 0 | — | — | 2 | −39.9% (1) | March 6, 2026 |
| Sainz Maria | Director | 1 | +18.9% (1) | 100% | 1 | −20.8% (1) | June 13, 2016 |
| Serbousek Jon Carl | CEO | 2 | −16.1% (2) | 0% | 0 | — | November 18, 2021 |
| Ajdler Arnaud | 10% owner | 1 | — | — | 0 | — | February 26, 2026 |
| Burzik Catherine M | Director | 1 | −35.6% (1) | 0% | 0 | — | November 19, 2021 |
| Buxton Emily | Chief Financial Officer | 1 | −1.7% (1) | 0% | 0 | — | May 20, 2013 |
| Capps Vickie L | Director | 1 | — | — | 0 | — | March 10, 2026 |
| Doug Rice | CFO | 1 | −35.6% (1) | 0% | 0 | — | November 19, 2021 |
| Engine Investments II, LLC | 10% owner | 1 | −21.0% (1) | 0% | 0 | — | July 7, 2025 |
| Engine Jet Capital, L.P. | 10% owner | 1 | — | — | 0 | — | May 7, 2026 |
| Engine Lift Capital, LP | 10% owner | 1 | −31.7% (1) | 0% | 0 | — | May 8, 2025 |
| Fujikawa Raymond | President Spine Fixation | 0 | — | — | 1 | −6.0% (1) | August 14, 2017 |
| Gero James | Director | 1 | +5.2% (1) | 100% | 0 | — | May 15, 2013 |
| Gillespie Geoffrey C | CAO | 0 | — | — | 1 | −45.1% (1) | February 5, 2025 |
| Goodwin Robert Allen II | President Biologics | 0 | — | — | 1 | −22.0% (1) | May 20, 2016 |
| Heggestad Mark A | Chief Financial Officer | 1 | −11.9% (1) | 0% | 0 | — | June 12, 2014 |
| Henneman John B III | Director | 1 | — | — | 0 | — | May 8, 2026 |
| Kenny Kevin J. | President of Global Spine | 0 | — | — | 1 | −50.0% (1) | May 26, 2023 |
| Maniar Shweta | Director | 0 | — | — | 1 | −44.3% (1) | April 5, 2023 |
| Michas Alexis P | 10% owner | 0 | — | — | 1 | — | August 18, 2026 |
| Milinazzo Alan | President & CEO | 1 | +16.3% (1) | 100% | 0 | — | November 9, 2010 |
When several insiders traded Orthofix Medical Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Orthofix Medical Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 7 buying crowds with six months of prices, it averaged +5.3% against the index. After 6 selling crowds, −17.5%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| August 31, 2026 | 3 selling | not yet | not yet | not yet |
| March 31, 2026 | 7 selling | −33.5% | −35.8% | not yet |
| August 29, 2025 | 3 selling | +1.2% | −19.1% | −56.5% |
| July 31, 2025 | 4 buying | +29.7% | +9.7% | −10.1% |
| May 30, 2025 | 3 buying | +23.4% | +26.4% | −44.0% |
| February 28, 2025 | 3 selling | −34.8% | −23.0% | −40.9% |
| November 30, 2021 | 5 buying | +14.0% | −1.5% | −32.1% |
| March 31, 2020 | 3 buying | −5.9% | −19.7% | −1.5% |
| June 30, 2016 | 4 selling | −3.6% | −23.7% | −8.2% |
| November 30, 2015 | 3 selling | +7.5% | +10.3% | −11.5% |
| June 30, 2015 | 2 buying | +6.8% | +18.2% | +25.5% |
| May 31, 2013 | 5 buying | −19.4% | −33.6% | −5.8% |